Stockreport

Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF -- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection -- Subject dosing commenced S [Read more]